Therefore, targeting PFK1, as well as its key activator fructose-2,6-bisphosphate (F-2,6-BP) produced by phosphofructokinase-2 (PFK2) (also called 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) in cancer cells), could be a novel and efficient strategy to increase the sensitivity to PI3K and YAP inhibitors. The gene discussed is PFKFB3; the disease is cancer.